Home > Insider Trading > Filing (0001104659-21-035758)

Filing Details

Accession Number:: 0001104659-21-035758
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-12 19:51:29
Reporting Period:: 2021-03-10

Accepted Time:: 2021-03-12 19:51:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc.	ICPT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1253170	Srinivas Akkaraju	C/O Intercept Pharmaceuticals, Inc. 10 Hudson Yards, Floor 37 New York NY 10001		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-03-10	73,441	$20.83	477,129	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-03-10	16,559	$21.55	493,688	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-03-12	147,000	$21.29	640,688	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	23,121	Direct

Footnotes

These purchases were executed in multiple trades at prices ranging from $20.50 to $21.30. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein.
These purchases were executed in multiple trades at prices ranging from $21.50 to $21.58. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
These purchases were executed in multiple trades at prices ranging from $21.03 to $21.50. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.